Silver Creek Pharmaceuticals key facts
as of Oct 2026- Operator of a biotechnology firm intended to develop therapies that improve the body's healing response and repair damaged tissue.
- Silver Creek Pharmaceuticals is valued at approximately $60.0M as of Oct 2026 (last reported valuation).
- It has raised $57.1M across 2 recorded rounds; the latest was Early Stage VC ($9.2M) in Jan 2022.
- Notable investors include Catalytik Group, Crocker Ventures, Lung, Mark Agne, National Heart — 8 tracked in total.
- Silver Creek Pharmaceuticals has filed 2 Form Ds with the SEC since 2016, most recently Feb 2022 ($9.2M sold to 22 investors).
- Status: Privately Held (backing).
Silver Creek Pharmaceuticals's last reported valuation, Feb 2018. Nothing priced has surfaced since.
- ·Watch Silver Creek Pharmaceuticals: the Monday email on marks, rounds and moves
Silver Creek Pharmaceuticals funding rounds
2 roundsWho backs Silver Creek Pharmaceuticals
8Silver Creek Pharmaceuticals valuation
Silver Creek Pharmaceuticals's last reported valuation was $60 million in Feb 2018. No priced round, secondary trade or fund mark has surfaced since.
How much has Silver Creek Pharmaceuticals raised?
Silver Creek Pharmaceuticals has raised $57.1 million in total; 2 of its rounds are on record. The largest on record was a $9.2 million early-stage round in Jan 2022.
Silver Creek Pharmaceuticals has filed 2 Form Ds with the SEC since 2016, most recently in Feb 2022 ($9.2 million sold to 22 investors).
Silver Creek Pharmaceuticals investors
8 investors are on record for Silver Creek Pharmaceuticals, including Catalytik Group, Crocker Ventures, Lung and Mark Agne. The early-stage round in Jan 2022 drew 22 investors.
About Silver Creek Pharmaceuticals
Operator of a biotechnology firm intended to develop therapies that improve the body's healing response and repair damaged tissue. The company offers novel regenerative medicines that stimulate stem cell-based regeneration of cardiovascular tissues after a cardiac infarction, providing patients with the required therapies to protect or repair heart tissue following a heart attack.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2010
- Employees
- 8
- Website
- silvercreekpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.